solabegron
Small moleculeexperimental
Solabegron is a drug which acts as a selective agonist for the β3 adrenergic receptor. It is being developed for the treatment of overactive bladder and irritable bowel syndrome. It has been shown to produce visceral analgesia by releasing somatostatin from adipocytes. — Wikipedia
Clinical trial activity
8 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2006 (NCT00343486)
Timeline
Indications
Mechanism of action
- Beta-3 adrenergic receptorAGONIST
ADRB3 agonist
Chemistry & pharmacology
Loading structure…
SMILES
O=C(O)c1cccc(-c2cccc(NCCNC[C@H](O)c3cccc(Cl)c3)c2)c1- Mol. weight
- 410.9 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaSolabegron ↗
- ChEMBLCHEMBL208427 ↗
Also known as
- 3'-((2-((2-(3-chlorophenyl)-2-hydroxyethyl)amino)ethyl)amino)-(1,1'-biphenyl)-3-carboxylic acid
- gw427353
- gw427353
- gw427353
- gw427353
- gw 427353
- gw-427353
- (r)-3'-((2-((2-(3-chlorophenyl)-2-hydroxyethyl)amino)ethyl)amino)-(1,1'-biphenyl)-3-carboxylic acid
- solabegron
- solabegron
- solabegron
- solabegron
- solabegron
- solabegron hydrochloride
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03594058 | Phase 2 | Jul 9, 2018 | Velicept Therapeutics, Inc. |
| NCT03475706 | Phase 2 | Feb 19, 2018 | Velicept Therapeutics, Inc. |
| NCT02938507 | Phase 1 | Oct 1, 2016 | Velicept Therapeutics, Inc. |
| NCT00501267 | Phase 1 | Jun 1, 2007 | GlaxoSmithKline |
| NCT00427596 | Phase 1 | Jan 1, 2007 | GlaxoSmithKline |
| NCT00401479 | Phase 1 | Oct 1, 2006 | GlaxoSmithKline |
| NCT00394186 | Phase 2 | Aug 1, 2006 | GlaxoSmithKline |
| NCT00343486 | Phase 2 | May 1, 2006 | GlaxoSmithKline |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 5 | 5 | 2 | 2006 |
| Velicept Therapeutics, Inc. | For profit | 3 | 3 | 2 | 2016 |
2 organizations
Page 1 / 1